Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 06 Nov 2023

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

in Cancer Molecular Targets and Therapeutics

Dingyuan Yang
Wenqiang Chen
Fei Lai
Mingxing Qiu
Jun Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1110807

2,012 views

Original Research

Published on 02 Nov 2023

Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation

in Cancer Molecular Targets and Therapeutics

Weifeng Liu
Zhijie Chu
Cheng Yang
Tianbao Yang
Yanhui Yang
Haigang Wu
Junjun Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1287797

3,278 views
4 citations

Original Research

Published on 02 Nov 2023

Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

in Cancer Molecular Targets and Therapeutics

Tieyan Wang
Dan Yu
Juanjuan Wang
Ningning Zhu
Xian-bin Tang
Xiuwen Chen
Xiao-min Su
Yu-gang Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.1250558

3,857 views
3 citations

Original Research

Published on 30 Oct 2023

Fanconi anemia pathway regulation by FANCI in prostate cancer

in Cancer Molecular Targets and Therapeutics

Heidi Kaljunen
Sinja Taavitsainen
Roosa Kaarijärvi
Eerika Takala
Ville Paakinaho
Matti Nykter
G. Steven Bova
Kirsi Ketola

Frontiers in Oncology

doi 10.3389/fonc.2023.1260826

3,156 views
3 citations

Review

Published on 27 Oct 2023

Role and therapeutic potential of DEAD-box RNA helicase family in colorectal cancer

in Cancer Molecular Targets and Therapeutics

Bichun Zheng
Xudong Chen
Qiaoyun Ling
Quan Cheng
Shaoshun Ye

Frontiers in Oncology

doi 10.3389/fonc.2023.1278282

4,180 views
1 citation

Review

Published on 26 Oct 2023

The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides

in Cancer Molecular Targets and Therapeutics

Ali Nejatie
Samantha S. Yee
Anna Jeter
Horacio Uri Saragovi

Frontiers in Oncology

doi 10.3389/fonc.2023.1261090

3,956 views
4 citations

Original Research

Published on 25 Oct 2023

Identification of prognosis-related lncRNAs and cell validation in lung squamous cell carcinoma based on TCGA data

in Cancer Molecular Targets and Therapeutics

Yishuang Cui
Yanan Wu
Mengshi Zhang
Yingze Zhu
Xin Su
Wenyue Kong
Xuan Zheng
Guogui Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1240868

2,207 views
2 citations

Review

Published on 24 Oct 2023

Lung cancer organoids: models for preclinical research and precision medicine

in Cancer Molecular Targets and Therapeutics

Yajing Liu
Yanbing Zhou
Pu Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1293441

9,652 views
7 citations

Case Report

Published on 18 Oct 2023

Immunohistochemistry combined with NGS to assist the differential diagnosis of multiple primary lung cancer with lymph node metastasis: a case report

in Cancer Molecular Targets and Therapeutics

Chang Liu
Shuai Zhang
Hong Yang
Yu Bai
Yanru Shen
Yi Ren

Frontiers in Oncology

doi 10.3389/fonc.2023.1260759

1,645 views

Brief Research Report

Published on 18 Oct 2023

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

in Cancer Molecular Targets and Therapeutics

Layal Al Mahmasani
Ghid Amhaz
Reine Abou Zeidane
Nathalie Chamseddine
Taha Hatab
Saad Sabbagh
Maya Charafeddine
Hazem I. Assi

Frontiers in Oncology

doi 10.3389/fonc.2023.1181375

1,518 views
2 citations

Case Report

Published on 18 Oct 2023

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Yingmei Wen
Yi Dong
Lina Yi
Guifang Yang
Mengxia Xiao
Qingqing Li
Chen Zhao
Dafu Ye
Yi Yao

Frontiers in Oncology

doi 10.3389/fonc.2023.1241475

2,225 views
3 citations

Review

Published on 16 Oct 2023

Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer

in Cancer Molecular Targets and Therapeutics

Min Gao
Yongwen Li
Peijun Cao
Hongyu Liu
Jun Chen
Shirong Kang

Frontiers in Oncology

doi 10.3389/fonc.2023.1216289

3,984 views
2 citations

Original Research

Published on 16 Oct 2023

The anti-cancer efficacy of a novel phenothiazine derivative is independent of dopamine and serotonin receptor inhibition

in Cancer Molecular Targets and Therapeutics

Marion Vanneste
Anita Venzke
Soumitra Guin
Andrew J. Fuller
Andrew J. Jezewski
Sarah R. Beattie
Damian J. Krysan
Marvin J. Meyers
Michael D. Henry

Frontiers in Oncology

doi 10.3389/fonc.2023.1295185

2,436 views
3 citations

Original Research

Published on 10 Oct 2023

Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study

in Cancer Molecular Targets and Therapeutics

Yanping Lin
Long Chen
Rong Li
Xin Liu
Quan Li
Jingjing Cai
Yaxi Du
Guangqiang Zhao
Xiaoxiong Wang
Zhenghai Shen

Frontiers in Oncology

doi 10.3389/fonc.2023.1156647

2,507 views
2 citations

Case Report

Published on 05 Oct 2023

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion

in Cancer Molecular Targets and Therapeutics

XiaoQing Li
JingFan Zheng
XinYi Li
YuYu Chen
Kang Liu
FangChao Li
Zhong Lu

Frontiers in Oncology

doi 10.3389/fonc.2023.1252221

2,203 views
8 citations

Review

Published on 04 Oct 2023

Use and accuracy of decision support systems using artificial intelligence for tumor diseases: a systematic review and meta-analysis

in Cancer Molecular Targets and Therapeutics

Robert Oehring
Nikitha Ramasetti
Sharlyn Ng
Roland Roller
Philippe Thomas
Axel Winter
Max Maurer
Simon Moosburner
Nathanael Raschzok
Can Kamali

Frontiers in Oncology

doi 10.3389/fonc.2023.1224347

4,993 views
9 citations